A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.

Biomed Res Int · 2015 · PMC4573229 · PMID 26421300

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

A clear trend existed across the risk groups with (older) males exhibiting numerically higher CR rates than (younger) females and CR rates numerically higher for NEPA than oral palonosetron in all gender/age risk groups ( Table 4 ). 4.3.2.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.